Lumos Diagnostics Discusses BARDA Partnership and FebriDx Expansion

Lumos Diagnostics Holdings Ltd. (AU:LDX) has released an update.

Lumos Diagnostics has announced an online briefing to discuss their partnership with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for the upcoming FebriDx® CLIA waiver study and FDA application. The webinar, set for 11 October 2024, will also address the non-dilutive funding received by Lumos and the expansion of FebriDx, a rapid respiratory test, for point-of-care settings. FebriDx has been FDA cleared since July 2023 as an aid in differentiating bacterial from non-bacterial acute respiratory infections.

For further insights into AU:LDX stock, check out TipRanks’ Stock Analysis page.